Back to List

Johnson & Johnson

jnj.com

At J&J, we have made it our business to advance better health. For more than 130 years, we have been committed to improving the health of individuals, families & communities around the world, including the most vulnerable and under served populations. Today, we continue to invest and collaborate to help solve some of the most complex global health challenges. By harnessing J&J’s breadth, scale and legacy of scientific innovation, we strive to change the trajectory of health for humanity.

Addressing critical public health challenges requires bold leadership and novel approaches.  Despite tremendous progress in medical science and technology during the last decades, significant health gaps remain for many people around the globe.

Emerging new global challenges will require collective effort and partnerships to deliver solutions. Johnson & Johnson Global Public Health (GPH) is the first fully dedicated organization within a healthcare company focused on combining innovative R&D, novel access programs, country-based operations and advocacy. GPH aims to ensure that treatments and technologies are available, affordable and accessible for the world’s most under served populations as we work to realize a world without disease.

Our GPH strategy tackles some of the world’s most pressing health challenges, targeting transformational health outcomes for individuals and communities. This includes aspirations to eliminate human immunodeficiency virus (HIV) and tuberculosis (TB), and reduce the burden of neglected tropical diseases and non-communicable diseases alongside addressing critical issues such as mental health and the threat of drug resistance and global pandemics.

As a global healthcare leader, Johnson & Johnson is at the forefront of addressing the world’s most intractable diseases. In 2018, we maintained our planned actions to reduce the burden of prominent diseases and are on track against our published targets, advancing better health for adults and children around the world.

Read more in our 2018 Health for Humanity report which highlights how we act and innovate with bold leadership and purpose to drive better health for all by eradicating and preventing disease, re-imagining how care is delivered and aiming to put good health within reach of everyone, everywhere.

PARTNERSHIPS

SHOWING 5 of 21 PARTNERSHIPS

See All

Access Accelerated Initiative

Tackling the growing burden of non-communicable diseases in low and middle-income countries and supporting...

Access Accelerated, Almirall, Astellas Pharma Inc, Bayer AG, Bristol-Myers Squibb, Celgene, Chiesi Farmaceutici, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly and Company, F. Hoffmann – La Roche Ltd., IFPMA, Johnson & Johnson, Menarini Group, Merck, MSD, Novartis Pharma AG, Pfizer Inc, Sanofi, Servier, Shionogi & Co., Ltd., Sumitomo Dainippon, Takeda Pharmaceutical Company Limited, UCB

SHOWING 5 of 21 PARTNERSHIPS

See All